ConductScience.org, home

Paper40833332

Prognostic immunoinflammatory and transcriptomic profiles in patients with pleural mesothelioma undergoing immunotherapy.

Mazzaschi G and 21 others. Immunotherapy, 2025. Cited by 2 papers, by iCite.

Cite this record

ConductScience Library. Prognostic immunoinflammatory and transcriptomic profiles in patients with pleural mesothelioma undergoing immunotherapy. Papers, record 40833332. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40833332

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Prognostic immunoinflammatory and transcriptomic profiles in patients with pleural mesothelioma undergoing immunotherapy.
PubMed
Journal
Immunotherapy
PubMed
Year
2025
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
2
iCite
Revised in PubMed
2026-08-21
PubMed

Authors22

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Mazzaschi GGiulia
2Rosati RRoberto
3D'Agnelli SSimona
4Minari RRoberta
5Trentini FFrancesca
6Tamarozzi PPrisca
7Manini MMartina
8Zinelli Ronzoni MMartina
9Dodi AAlessandra
10Gnetti LLetizia
11Bottarelli LLorena
12Azzoni CCinzia
13Martines GGianmarco
14Pluchino MMonica
15Toscani IIlaria
16Leonetti AAlessandro
17Perrone FFabiana
18Bordi PPaola
19Bocchialini GGiovanni
20Ampollini LLuca

Source PubMed

See all 22 authorsDownload CSV of authors

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
ImmunotherapyMajor topic
Pleural NeoplasmsMajor topic
MesotheliomaMajor topic
Humans
Male
Female
Middle Aged
Aged
Prognosis
Transcriptome
Tumor Microenvironment
Nivolumab
Biomarkers, Tumor
Ipilimumab
Mesothelioma, Malignant

Source PubMed

Download CSV of topics

References34

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
125791825Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database.J Surg Res2015https://conductscience.org/library/papers/25791825PubMed
233485464First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.Lancet2021https://conductscience.org/library/papers/33485464PubMed
333837910Malignant pleural mesothelioma: clinical experience and prognostic value of derived neutrophil-to-lymphocyte ratio and PD-L1 expression.Clin Transl Oncol2021https://conductscience.org/library/papers/33837910PubMed
436773602Genomic and transcriptomic analyses identify a prognostic gene signature and predict response to therapy in pleural and peritoneal mesothelioma.Cell Rep Med2023https://conductscience.org/library/papers/36773602PubMed
528777143
Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors.
Adv Anat Pathol2017https://conductscience.org/library/papers/28777143PubMed
629203879QuPath: Open source software for digital pathology image analysis.Sci Rep2017https://conductscience.org/library/papers/29203879PubMed
716621962ULBPs, human ligands of the NKG2D receptor, stimulate tumor immunity with enhancement by IL-15.Blood2006https://conductscience.org/library/papers/16621962PubMed
826694968CRTAM determines the CD4+ cytotoxic T lymphocyte lineage.J Exp Med2016https://conductscience.org/library/papers/26694968PubMed
931924474Regulatory T Cells Restrain Interleukin-2- and Blimp-1-Dependent Acquisition of Cytotoxic Function by CD4+ T Cells.Immunity2020https://conductscience.org/library/papers/31924474PubMed
1030642544The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC.Lung Cancer2019https://conductscience.org/library/papers/30642544PubMed
1112478000Correlation of serum IL-2, IL-6 and IL-10 levels with International Prognostic Index in patients with aggressive non-Hodgkin's lymphoma.Am J Clin Oncol2002https://conductscience.org/library/papers/12478000PubMed
1226155428The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: A comprehensive analysis reveals prognostic immune markers.Oncoimmunology2015https://conductscience.org/library/papers/26155428PubMed
1334656227Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial.Lancet Oncol2021https://conductscience.org/library/papers/34656227PubMed
1438396241Clonal gene signatures predict prognosis in mesothelioma and lung adenocarcinoma.NPJ Precis Oncol2024https://conductscience.org/library/papers/38396241PubMed
1530909496MYC Oncogene Contributions to Release of Cell Cycle Brakes.Genes (Basel)2019https://conductscience.org/library/papers/30909496PubMed
1634910940Cytotoxic CD4+ T cells in cancer: Expanding the immune effector toolbox.Immunity2021https://conductscience.org/library/papers/34910940PubMed
1738036250Brief Report: Real-World Toxicity and Survival of Combination Immunotherapy in Pleural Mesothelioma-RIOMeso.J Thorac Oncol2024https://conductscience.org/library/papers/38036250PubMed
1833637530Tumor-specific cytolytic CD4 T cells mediate immunity against human cancer.Sci Adv2021https://conductscience.org/library/papers/33637530PubMed
1939814199
A randomised phase III study of bevacizumab and carboplatin-pemetrexed chemotherapy with or without atezolizumab as first-line treatment for advanced pleural mesothelioma: results of the ETOP 13-18 BEAT-meso trial.
Ann Oncol2025https://conductscience.org/library/papers/39814199PubMed
2032676358Clinical significance of histologic subtyping of malignant pleural mesothelioma.Transl Lung Cancer Res2020https://conductscience.org/library/papers/32676358PubMed

See all 34 referencesDownload CSV of references

Cited by2

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.

PMIDTitleJournalYearIn PapersSource
41826598Multi-omics integration reveals tumor and microenvironmental heterogeneity in malignant pleural mesothelioma.Discov Oncol2026https://conductscience.org/library/papers/41826598PubMed
41767494Advances in immunotherapy for thyroid malignancies: from molecular targets to clinical outcomes.Front Med (Lausanne)2026https://conductscience.org/library/papers/41767494PubMed

Download CSV of cited by

Genes7

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40833332

GET https://conductscience.org/api/papers/v1/40833332/authors?page=2